ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,654.30
0.26%
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs Yen
157.2625
0.01%
Brent Oil
81.295
0.00%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) ニュース

IONS

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:IONS
日付受信時刻ニュースソース見出しコード企業名
2024/05/3120 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/3120 : 00PR Newswire (US)Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedemaNASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/2820 : 00PR Newswire (US)Ionis to hold donidalorsen Phase 3 data webcastNASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/2320 : 00PR Newswire (US)New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)NASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/1620 : 30GlobeNewswire Inc.Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisNASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/1620 : 30PR Newswire (US)Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisNASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/1620 : 00PR Newswire (US)Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/1520 : 05PR Newswire (US)Ionis to host 2024 virtual Annual Meeting of StockholdersNASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/1406 : 25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/0805 : 55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/0804 : 55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/0800 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
2024/05/0720 : 00PR Newswire (US)Ionis reports first quarter 2024 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
2024/04/2520 : 00PR Newswire (US)Ionis Publishes 2023 Corporate Responsibility ReportNASDAQ:IONSIonis Pharmaceuticals Inc
2024/04/2320 : 05PR Newswire (US)Ionis to hold first quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
2024/04/0722 : 48PR Newswire (US)Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
2024/04/0120 : 05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/2820 : 05PR Newswire (US)Ionis to hold olezarsen Phase 3 data webcastNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/2521 : 18PR Newswire (US)Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meetingNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/1320 : 00PR Newswire (US)Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASHNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0621 : 30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0509 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0509 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0509 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0509 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/03/0509 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/2923 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/2923 : 05PR Newswire (US)Ionis announces new chief global product strategy officer to lead next phase of commercial growthNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/2821 : 05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/02/2201 : 17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:IONS

最近閲覧した銘柄

SPI
SP500
S&P 500
NYSE
AXP
American Express
NYSE
DIS
Walt Disney
USOTC
ADDYY
Adidas (QX)
AMEX
SPY
SPDR S&P 500
USOTC
BNPQY
BNP Paribas (QX)
USOTC
BASFY
BASF (QX)
CCOM
US500
US 500
USOTC
RHHBY
Roche (QX)
AMEX
XLF
Financial Select Sector
COIN
ETHUSD
Ethereum
NASDAQ
AAPL
Apple
FX
USDEUR
US Dollar vs Euro
NYSE
CVX
Chevron
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有